(OPRX) OPTIMIZERx - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 93m USD | Total Return: -58% in 12m
Avg Turnover: 2.09M
EPS Trend: 94.5%
Qual. Beats: 0
Rev. Trend: 97.3%
Qual. Beats: 0
Warnings
Altman Z'' -1.40 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
OptimizeRx Corporation (OPRX) is a healthcare technology firm specializing in digital communication between pharmaceutical manufacturers, healthcare providers (HCPs), and patients. Its core business model utilizes a proprietary Dynamic Audience Activation Platform and machine learning to deliver point-of-care messaging, such as affordability alerts and clinical data, directly into electronic health record (EHR) systems and e-prescribing workflows.
The company operates within the health care technology sector, where integration into clinical software is a significant barrier to entry due to the technical complexity of EHR interoperability. OptimizeRx expands its reach through omnichannel media execution, including programmatic display, social media, and pharmacy-level alerts designed to improve medication adherence and transparency in drug pricing.
For more detailed financial metrics and valuation analysis, consider exploring the data available on ValueRay.
- DAAP platform adoption accelerates pharmaceutical brand integration and revenue growth
- Electronic health record partnership expansion drives higher physician network reach
- Pharma marketing budget shifts toward digital point-of-care advertising solutions
- Integration of Healthy Big Data acquisition impacts consolidated operating margins
- Regulatory changes to healthcare data privacy affect predictive audience targeting capabilities
| Net Income: 6.84m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 4.81 > 1.0 |
| NWC/Revenue: 42.58% < 20% (prev 35.35%; Δ 7.23% < -1%) |
| CFO/TA 0.09 > 3% & CFO 14.4m > Net Income 6.84m |
| Net Debt (3.92m) to EBITDA (18.8m): 0.21 < 3 |
| Current Ratio: 5.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.8m) vs 12m ago 1.57% < -2% |
| Gross Margin: 69.05% > 18% (prev 0.64%; Δ 6.84k% > 0.5%) |
| Asset Turnover: 64.08% > 50% (prev 56.25%; Δ 7.83% > 0%) |
| Interest Coverage Ratio: 2.84 > 6 (EBITDA TTM 18.8m / Interest Expense TTM 5.15m) |
| A: 0.27 (Total Current Assets 56.2m - Total Current Liabilities 10.5m) / Total Assets 167.3m |
| B: -0.48 (Retained Earnings -79.7m / Total Assets 167.3m) |
| C: 0.09 (EBIT TTM 14.6m / Avg Total Assets 167.5m) |
| D: -2.12 (Book Value of Equity -79.7m / Total Liabilities 37.7m) |
| Altman-Z'' = -1.40 = CCC |
| DSRI: 0.88 (Receivables 32.9m/32.8m, Revenue 107.3m/94.4m) |
| GMI: 0.93 (GM 69.05% / 64.13%) |
| AQI: 0.96 (AQ_t 0.66 / AQ_t-1 0.69) |
| SGI: 1.14 (Revenue 107.3m / 94.4m) |
| TATA: -0.05 (NI 6.84m - CFO 14.4m) / TA 167.3m) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of June 01, 2026, the stock is trading at USD 5.19 with a total of 528,524 shares traded.
Over the past week, the price has changed by +5.06%,
over one month by -16.69%,
over three months by -29.77% and
over the past year by -57.98%.
OPTIMIZERx has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy OPRX.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.5 | 121.6% |
P/E Trailing = 13.7222
P/E Forward = 5.3706
P/S = 0.8636
P/B = 0.7152
P/EG = 1.6078
Revenue TTM = 107.3m USD
EBIT TTM = 14.6m USD
EBITDA TTM = 18.8m USD
Long Term Debt = 21.3m USD (from longTermDebt, last quarter)
Short Term Debt = 2.18m USD (from shortTermDebt, last quarter)
Debt = 24.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 373k
Net Debt = 3.92m USD (calculated: Debt 24.1m - CCE 20.2m)
Enterprise Value = 96.6m USD (92.7m + Debt 24.1m - CCE 20.2m)
Interest Coverage Ratio = 2.84 (Ebit TTM 14.6m / Interest Expense TTM 5.15m)
EV/FCF = 6.74x (Enterprise Value 96.6m / FCF TTM 14.3m)
FCF Yield = 14.83% (FCF TTM 14.3m / Enterprise Value 96.6m)
FCF Margin = 13.35% (FCF TTM 14.3m / Revenue TTM 107.3m)
Net Margin = 6.37% (Net Income TTM 6.84m / Revenue TTM 107.3m)
Gross Margin = 69.05% ((Revenue TTM 107.3m - Cost of Revenue TTM 33.2m) / Revenue TTM)
Gross Margin QoQ = 69.89% (prev 74.75%)
Tobins Q-Ratio = 0.58 (Enterprise Value 96.6m / Total Assets 167.3m)
Interest Expense / Debt = 21.39% (Interest Expense 5.15m / Debt 24.1m)
Taxrate = 26.16% (1.82m / 6.95m)
NOPAT = 10.8m (EBIT 14.6m * (1 - 26.16%))
Current Ratio = 5.37 (Total Current Assets 56.2m / Total Current Liabilities 10.5m)
Debt / Equity = 0.19 (Debt 24.1m / totalStockholderEquity, last quarter 129.6m)
Debt / EBITDA = 0.21 (Net Debt 3.92m / EBITDA 18.8m)
Debt / FCF = 0.27 (Net Debt 3.92m / FCF TTM 14.3m)
Total Stockholder Equity = 124.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.08% (Net Income 6.84m / Total Assets 167.3m)
RoE = 3.34% (Net Income TTM 6.84m / Total Stockholder Equity 204.6m)
RoCE = 6.47% (EBIT 14.6m / Capital Employed (Equity 204.6m + L.T.Debt 21.3m))
RoIC = 7.78% (NOPAT 10.8m / Invested Capital 138.8m)
WACC = 12.99% (E(92.7m)/V(116.8m) * Re(12.26%) + D(24.1m)/V(116.8m) * Rd(21.39%) * (1-Tc(0.26)))
Discount Rate = 12.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 1.46%
[DCF] Terminal Value 64.47% ; FCFF base≈11.1m ; Y1≈12.8m ; Y5≈18.8m
[DCF] Fair Price = 8.02 (EV 154.5m - Net Debt 3.92m = Equity 150.5m / Shares 18.8m; r=12.99% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.47 | EPS CAGR: 89.14% | SUE: -0.27 | # QB: 0
Revenue Correlation: 97.26 | Revenue CAGR: 25.04% | SUE: 0.47 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=N/A | Revisions=-20% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.24 | Chg30d=N/A | Revisions=-20% | Analysts=6
EPS current Year (2026-12-31): EPS=0.92 | Chg30d=-2.65% | Revisions=+20% | GrowthEPS=-12.7% | GrowthRev=-11.0%
EPS next Year (2027-12-31): EPS=1.06 | Chg30d=-5.14% | Revisions=-20% | GrowthEPS=+15.3% | GrowthRev=+11.2%
[Analyst] Revisions Ratio: -20%